SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Pluvia's Fist.com - Pluvia's Plays & Portfolio
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Pluvia who wrote (977)9/12/2000 11:57:08 PM
From: Valueman  Read Replies (1) of 1766
 
7. Patients in both studies had failed previous anti-HIV treatment due to drug resistance. So both Durant and the T-20 study used the same type of patient.

Even a cursory examination of the two trials shows that the population of patients were significantly different in their level of previous exposure to ARVs, number of mutations, CD4 counts, etc. Your comparison of the two trials is flawed.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News